期刊文献+

HIV-1 Gag抗原HLA-A*0201限制性低亲和性CTL表位预测及改造分析

Prediction and modificatory analysis on the HLA-A~*0201 restricted CTL epitopes with low affinity from HIV-1 Gag antigen
下载PDF
导出
摘要 初步筛选HIV-1 Gag抗原的HLA-A*0201限制性低亲和性CTL表位,预测并初步鉴定修饰后的表位与HLA-A*0201之间亲和性的变化。采用超基序、蛋白酶解预测等相结合的办法筛选HLA-A*0201限制性低亲和性CTL表位,通过氨基酸置换适当修饰,并以T2细胞株测定肽与HLA-A*0201分子的亲和力和稳定性试验来评价修饰后表位与HLA-A*0201之间亲和性。结果:筛选出3个低亲和性CTL候选表位,经修饰后的表位与HLA-A*0201之间的亲和性均有不同程度的提高。YIYKRWIIL(259-267Y1),YQANFLGKI(429-437Y1)和YTNNPPIPV(249-257Y1)与HLA-A*0201呈高亲和力结合,荧光系数(flurorescene index,FI)分别为2.68、2.54和2.35,同时肽-HLA-A*0201复合物半数解离时间(dissociation complex50,DC50)均大于8h。预测的低亲和力表位经过修饰可能会成为潜在的HLA-A*0201限制性表位。 The HLA-A*0201 restricted CTL epitopes with low affinity was screened by CTL epitope prediction software based on the super motif and proteasome cleavage probability,and it was favorably modified through amino acid substitution and analyzed by computer. Meanwhile,the affinity and stability between peptides and HLA-A*0201 molecule was determined by using the T2 cell strain and evaluated by means of the stability test. In this way,three candidate CTL epitopes with low affinity were screened. The affinity of t...
出处 《现代免疫学》 CAS CSCD 北大核心 2008年第1期37-40,共4页 Current Immunology
基金 国家自然科学基金资助项目(30600527)
关键词 HIV-1 CTL 表位 HIV-1 CTL epitope
  • 相关文献

参考文献14

  • 1[1]Sparacio S,Zeilfelder U,Pfeiffer T,et al.Membrane fusion between retroviral particles:host range extension and vaccine prospects[J].Virology,2000,271 (2):248-252.
  • 2[2]Goulder PJ,Rowland-Jones SL,McMichael AJ,et al.Anti-HIV cellular immunity:recent advances towards vaccine design[J].AIDS,1999,13 (SupplA):S121-136.
  • 3[3]Talwar GP,Diwan M,Razvi F,et al.The impact of new technologies on vaccines[J].Natl Med J India,1999,12(6):274-280.
  • 4[4]Borrow PH,Lewicki BH,Hahn GM.Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection[J].J Virol,1994,68:6103-6110.
  • 5[5]Klein MR,van Baalen CA,Holwerda AM,et al.Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection:a longitudinal analysis of rapid progressors and long-term asymptomatics[J].J Exp Med,1995,181:1365-1372.
  • 6[6]Rosenberg SA,Yang JC,Schwartzentruber DJ,et al.Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma[J].Nat Med,1998,4(3):321-327.
  • 7[7]Lin ZH,Wu YZ,Wei YL,et al.A rapid method for quantitative prediction of high affinity CTL epitopes:QSAR studies on peptides having affinity with the class Ⅰ MHC molecular HLA-A* 2.1[J].Lett Peptide Sci,2003,10 (1):15-23.
  • 8[8]Parker KC,Bednarek MA,Coligan JE.Scheme for ranking potential HLA-A2 binding peptides base on independent binding of individual peptide side-chains[J].J Immunol,1994,152(1):163-175.
  • 9[9]Barouch DH,Santra S,Schmitz JE,et al.Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination[J].Science,2000,290(5491):486-492.
  • 10[10]Lu W,Wu X,Lu Y,et al.Therapeutic dendritic-cell vaccine for simian AIDS[J].Nat Med,2003,9 (1):27-32.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部